Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo.

Protein tyrosine phosphorylation is a major regulator of bone metabolism. Tyrosine phosphatases participate in regulating phosphorylation, but roles of specific phosphatases in bone metabolism are largely unknown. We demonstrate that young (<12 weeks) female mice lacking tyrosine phosphatase epsilon (PTPepsilon) exhibit increased trabecular bone mass due to cell-specific defects in osteoclast function. These defects are manifested in vivo as reduced association of osteoclasts with bone and as reduced serum concentration of C-terminal collagen telopeptides, specific products of osteoclast-mediated bone degradation. Osteoclast-like cells are generated readily from PTPepsilon-deficient bone-marrow precursors. However, cultures of these cells contain few mature, polarized cells and perform poorly in bone resorption assays in vitro. Podosomes, structures by which osteoclasts adhere to matrix, are disorganized and tend to form large clusters in these cells, suggesting that lack of PTPepsilon adversely affects podosomal arrangement in the final stages of osteoclast polarization. The gender and age specificities of the bone phenotype suggest that it is modulated by hormonal status, despite normal serum levels of estrogen and progesterone in affected mice. Stimulation of bone resorption by RANKL and, surprisingly, Src activity and Pyk2 phosphorylation are normal in PTPepsilon-deficient osteoclasts, indicating that loss of PTPepsilon does not cause widespread disruption of these signaling pathways. These results establish PTPepsilon as a phosphatase required for optimal structure, subcellular organization, and function of osteoclasts in vivo and in vitro.

[1]  M. Aepfelbacher,et al.  Podosomes: adhesion hot-spots of invasive cells. , 2003, Trends in cell biology.

[2]  P. Matsudaira,et al.  Macrophage podosomes assemble at the leading lamella by growth and fragmentation , 2003, The Journal of cell biology.

[3]  A. Elson,et al.  Tyrosine Phosphatase-ε Activates Src and Supports the Transformed Phenotype of Neu-induced Mammary Tumor Cells* , 2003, The Journal of Biological Chemistry.

[4]  G. Shohat,et al.  Protein Tyrosine Phosphatase E Inhibits Signaling by Mitogen-Activated Protein Kinases , 2003 .

[5]  G. Rodan,et al.  PYK2 Autophosphorylation, but Not Kinase Activity, Is Necessary for Adhesion-induced Association with c-Src, Osteoclast Spreading, and Bone Resorption* , 2003, The Journal of Biological Chemistry.

[6]  N. Tanuma,et al.  Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPɛC , 2003, Oncogene.

[7]  Sakae Tanaka,et al.  Regulation of cytochrome c oxidase activity by c-Src in osteoclasts , 2003, The Journal of cell biology.

[8]  F. Saltel,et al.  Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. , 2003, Molecular biology of the cell.

[9]  H. Aasheim,et al.  Expression of Human Protein Tyrosine Phosphatase Epsilon in Leucocytes: a Potential ERK Pathway‐Regulating Phosphatase , 2002, Scandinavian journal of immunology.

[10]  N. Tanuma,et al.  Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling. , 2001, Blood.

[11]  P G Drake,et al.  Structural and Evolutionary Relationships among Protein Tyrosine Phosphatase Domains , 2001, Molecular and Cellular Biology.

[12]  K. Lau,et al.  Antisense Oligodeoxynucleotide Evidence That a Unique Osteoclastic Protein‐Tyrosine Phosphatase Is Essential for Osteoclastic Resorption , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  A. Elson,et al.  Regulation of Protein-tyrosine Phosphatases α and ε by Calpain-mediated Proteolytic Cleavage* , 2001, The Journal of Biological Chemistry.

[14]  S. Rockman,et al.  Functional Abnormalities in Protein Tyrosine Phosphatase ε-Deficient Macrophages☆ , 2001 .

[15]  B. Neel,et al.  Combinatorial control of the specificity of protein tyrosine phosphatases. , 2001, Current opinion in cell biology.

[16]  J. Clausen,et al.  Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling. , 2001, The Biochemical journal.

[17]  W. Hurlburt,et al.  Biochemical characterization of osteo-testicular protein tyrosine phosphatase and its functional significance in rat primary osteoblasts. , 2001, Biochemistry.

[18]  D. Bowtell,et al.  Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, αvβ3 Integrin-Mediated Signaling, Cell Adhesion, and Osteoclast Motility , 2001, The Journal of cell biology.

[19]  G. Rodan,et al.  In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. , 2000, Endocrinology.

[20]  N. Tanuma,et al.  Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. , 2000, The Journal of biological chemistry.

[21]  A. Elson,et al.  Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control , 2000, Oncogene.

[22]  B. Attali,et al.  Hypomyelination and increased activity of voltage‐gated K+ channels in mice lacking protein tyrosine phosphatase ϵ , 2000, The EMBO journal.

[23]  J. Mönkkönen,et al.  Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.

[24]  D. Holt,et al.  A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. , 2000, Chemistry & biology.

[25]  J. Dixon,et al.  Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. , 2000, Seminars in immunology.

[26]  A. Elson Protein tyrosine phosphatase ε increases the risk of mammary hyperplasia and mammary tumors in transgenic mice , 1999, Oncogene.

[27]  R. Baron,et al.  The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice. , 1999, Bone.

[28]  K. Takagi,et al.  Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. , 1999, The American journal of pathology.

[29]  S. Aota,et al.  Molecular diversity of cell-matrix adhesions. , 1999, Journal of cell science.

[30]  J. Sap,et al.  Receptor protein tyrosine phosphatase α activates Src-family kinases and controls integrin-mediated responses in fibroblasts , 1999, Current Biology.

[31]  K. Lim,et al.  Targeted disruption of the tyrosine phosphatase PTPα leads to constitutive downregulation of the kinases Src and Fyn , 1999, Current Biology.

[32]  M. Šuša,et al.  A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. , 1999, Bone.

[33]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Rodan,et al.  PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. , 1998, The Journal of clinical investigation.

[35]  G. Rodan,et al.  Alendronate inhibition of protein-tyrosine-phosphatase-meg1. , 1997, Biochemical pharmacology.

[36]  M. Gresser,et al.  How Does Alendronate Inhibit Protein-tyrosine Phosphatases?* , 1997, The Journal of Biological Chemistry.

[37]  N. Udagawa,et al.  Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. , 1997, Bone.

[38]  K. Lau,et al.  Molecular cloning and expression of a unique rabbit osteoclastic phosphotyrosyl phosphatase. , 1996, The Biochemical journal.

[39]  C. Leu,et al.  Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Rodan,et al.  Human protein tyrosine phosphatase‐σ: Alternative splicing and inhibition by bisphosphonates , 1996 .

[41]  J. Dixon,et al.  Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST-PTP, in rat osteoblast-like cells. , 1996, Endocrinology.

[42]  K. Kikuchi,et al.  Molecular cloning of a novel cytoplasmic protein tyrosine phosphatase PTPε , 1996 .

[43]  P. Leder,et al.  Identification of a cytoplasmic, phorbol ester-inducible isoform of protein tyrosine phosphatase epsilon. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Elson,et al.  Protein-tyrosine Phosphatase ϵ , 1995, The Journal of Biological Chemistry.

[45]  A. Ullrich,et al.  Selective Down-regulation of the Insulin Receptor Signal by Protein-tyrosine Phosphatases α and ε (*) , 1995, The Journal of Biological Chemistry.

[46]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[47]  J. Dixon,et al.  Identification of a hormonally regulated protein tyrosine phosphatase associated with bone and testicular differentiation. , 1994, The Journal of biological chemistry.

[48]  T. Yoneda,et al.  Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Baron,et al.  Osteoclasts express high levels of pp60c-src in association with intracellular membranes , 1992, The Journal of cell biology.

[50]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[51]  Xinyang Zheng,et al.  Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase , 1992, Nature.

[52]  K. Väänänen,et al.  Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  S. Kellie,et al.  Cell/substratum adhesions in RSV-transformed rat fibroblasts. , 1991, Experimental cell research.

[54]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[55]  Haruo,et al.  Structural diversity and evolution of human receptor‐like protein tyrosine phosphatases. , 1990, The EMBO journal.

[56]  W. T. Chen,et al.  Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. , 1989, The Journal of experimental zoology.

[57]  A. Teti,et al.  The distribution of podosomes in osteoclasts cultured on bone laminae: Effect of retinol , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  Y. Wang,et al.  Alpha-actinin-containing aggregates in transformed cells are highly dynamic structures , 1987, The Journal of cell biology.

[60]  A. Teti,et al.  Rous sarcoma virus-transformed fibroblasts and cells of monocytic origin display a peculiar dot-like organization of cytoskeletal proteins involved in microfilament-membrane interactions. , 1987, Experimental cell research.

[61]  P. Comoglio,et al.  Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. , 1985, Experimental cell research.

[62]  L. Naldini,et al.  Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures , 1984, The Journal of cell biology.

[63]  S. Pfeffer,et al.  Molecular Biology of the Cell , 2021, Biophysics for Beginners.

[64]  A. R. Goldberg,et al.  Rous-sarcoma-virus-transformed fibroblasts having low levels of plasminogen activator. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Shohat,et al.  Protein tyrosine phosphatase epsilon inhibits signaling by mitogen-activated protein kinases. , 2003, Molecular cancer research : MCR.

[66]  A. Elson,et al.  Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells. , 2003, The Journal of biological chemistry.

[67]  N. Tanuma,et al.  Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C. , 2003, Oncogene.

[68]  S. Rockman,et al.  Functional abnormalities in protein tyrosine phosphatase epsilon-deficient macrophages. , 2001, Biochemical and biophysical research communications.

[69]  R. Baron,et al.  Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. , 2001, Bone.

[70]  A. Elson,et al.  Regulation of protein-tyrosine phosphatases alpha and epsilon by calpain-mediated proteolytic cleavage. , 2001, The Journal of biological chemistry.

[71]  A. Elson Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. , 1999, Oncogene.

[72]  N. Tanuma,et al.  Distinct promoters control transmembrane and cytosolic protein tyrosine phosphatase epsilon expression during macrophage differentiation. , 1999, European journal of biochemistry.

[73]  G. Rodan,et al.  Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  K. Kikuchi,et al.  Molecular cloning of a novel cytoplasmic protein tyrosine phosphatase PTP epsilon. , 1996, Biochemical and biophysical research communications.